PhoreMost
Biopharmaceutical company collaborates to progress drug discovery programmes
PhoreMost, UK-based biopharmaceutical company, has entered into a collaboration with o2h discovery (o2h) — an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. Read more
UK biopharma company completes funding round to enter drug discovery
UK-based biopharmaceutical company, PhoreMost, has completed a Series A investment round worth £11 million, which will be used to expand operations on the Babraham Research Campus and progress several novel drug targets. Read more
Innovate UK funds partnership for development of small-molecule drugs
Cancer immune-oncology company, NeoPhore, and developer of a next-generation phenotypic screening platform, PhoreMost, have been granted funding from Innovate UK in support of the development of novel small-molecule cancer immunotherapy programme. Read more
Collaborative agreement signed for identification of novel drug targets
PhoreMost, UK-based biopharmaceutical company, has signed a collaborative agreement with Plexxikon, the small molecule structure-guided R&D centre of Daiichi Sankyo, for the identification of novel drug targets. Read more
Fund manager invests in spin out immune-oncology company NeoPhore
UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. Read more
The undruggables: Collaboration aims to uncover new therapies for neurodegenerative disorders
Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. Read more
PhoreMost awarded £1.4M Innovate UK funding to develop lead oncology programme
PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers. Read more
